FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Stack Library

Classic GH Stack

GH Optimizationintermediate

95

synergy

95
Share
Peptides

2

Avg Daily mcg

600

Level

intermediate

Added

May 17, 2026

Overview

The Classic GH Stack — CJC-1295 paired with Ipamorelin — is the most clinically documented peptide combination in regenerative medicine and the gold standard for growth hormone optimization through secretagogues. It earns a synergy score of 95/100 because the two peptides operate through entirely separate receptor systems that, when activated together, produce GH output greater than the sum of either alone. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog. It binds to GHRH receptors on pituitary somatotroph cells, providing the primary signal for GH synthesis and release. Modified from native GHRH with a longer half-life, CJC-1295 (without DAC) produces a physiologically timed GH pulse when administered. It primes the pituitary, loading it with GH ready for release. Ipamorelin is a GHRP (growth hormone-releasing peptide) — specifically a ghrelin receptor agonist. It stimulates GH release through the ghrelin pathway, entirely independent of the GHRH receptor that CJC-1295 activates. Ipamorelin is uniquely selective: it stimulates GH release without significantly affecting cortisol, prolactin, ACTH, or appetite — a cleaner profile than other GHRPs like GHRP-2 or GHRP-6. When administered together, CJC-1295 prepares the pituitary (GHRH pathway) and Ipamorelin triggers the release (ghrelin pathway). Research on co-administration of GHRH analogs and GHRPs consistently shows GH output 200–300% greater than either compound alone, approaching supraphysiological levels from purely secretagogue-driven mechanisms — without exogenous GH. Administered before bed on an empty stomach, this stack amplifies the natural nocturnal GH pulse. Users typically report improved sleep quality within the first week, enhanced body composition (increased lean mass, reduced fat) within 4–8 weeks, and improved recovery and skin quality within 8–12 weeks. Standard cycle: 12 weeks on, 4 weeks off. Baseline and mid-cycle IGF-1 and fasting glucose monitoring is recommended.

Dosing Protocol

CJC-1295

Every day· subcutaneous

Read more about CJC-1295 →

300 mcg

per dose

Ipamorelin

Every day· subcutaneous

Read more about Ipamorelin →

300 mcg

per dose

Goals & Evidence

GH optimizationBody compositionRecoveryAnti-agingSleep quality
Evidence tier:Human Data

Warnings

  • Elevated GH/IGF-1 carries long-term risk tradeoffs. Not appropriate for anyone with cancer history. Monitor IGF-1 and fasting glucose.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.